Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy January 9, 2023May 23, 2023
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases November 16, 2020August 16, 2022
Prana provides regulatory update for PBT2 for the treatment of Huntington disease November 2, 2016August 16, 2022
